<SEC-DOCUMENT>0001437749-26-012303.txt : 20260415
<SEC-HEADER>0001437749-26-012303.hdr.sgml : 20260415
<ACCEPTANCE-DATETIME>20260415080513
ACCESSION NUMBER:		0001437749-26-012303
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260415
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260415
DATE AS OF CHANGE:		20260415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REVIVA PHARMACEUTICALS HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001742927
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38634
		FILM NUMBER:		26862571

	BUSINESS ADDRESS:	
		STREET 1:		10080 N WOLFE ROAD
		STREET 2:		SUITE SW3-200
		CITY:			CUPERTINO
		STATE:			CA
		ZIP:			95014
		BUSINESS PHONE:		4085018881

	MAIL ADDRESS:	
		STREET 1:		10080 N WOLFE ROAD
		STREET 2:		SUITE SW3-200
		CITY:			CUPERTINO
		STATE:			CA
		ZIP:			95014

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tenzing Acquisition Corp.
		DATE OF NAME CHANGE:	20180606
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rvph20260414_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:rvph="http://www.rvph.com/20260415"><head>
	<title>rvph20260414_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 4/14/2026 11:10:47 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20268K" name="dei:AmendmentFlag" id="ixv-407">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20268K" name="dei:EntityCentralIndexKey" id="ixv-408">0001742927</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="rvph-20260415.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20268K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2026-04-15</xbrli:startDate>
<xbrli:endDate>2026-04-15</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20268K" name="dei:DocumentType" id="ixv-418">8-K</ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b>&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934</b>&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported): <b><ix:nonNumeric contextRef="d20268K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-419">April 15, 2026</ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20268K" name="dei:EntityRegistrantName" id="ixv-420">REVIVA PHARMACEUTICALS HOLDINGS, INC.</ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:14.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20268K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-421">Delaware</ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:14.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20268K" name="dei:EntityFileNumber" id="ixv-422">001-38634</ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:14.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20268K" name="dei:EntityTaxIdentificationNumber" id="ixv-423">85-4306526</ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:14.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction<br/>
			of incorporation)</div>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:14.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission File Number)</div>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:14.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(IRS Employer<br/>
			Identification No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20268K" name="dei:EntityAddressAddressLine1" id="ixv-424">10080 N Wolfe Road</ix:nonNumeric>, <ix:nonNumeric contextRef="d20268K" name="dei:EntityAddressAddressLine2" id="ixv-425">Suite SW3-200</ix:nonNumeric>, <ix:nonNumeric contextRef="d20268K" name="dei:EntityAddressCityOrTown" id="ixv-426">Cupertino</ix:nonNumeric>, <ix:nonNumeric contextRef="d20268K" name="dei:EntityAddressStateOrProvince" id="ixv-427">CA</ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align:bottom;width:auto;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>95014</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices)</div>
			</td>
			<td style="vertical-align:top;width:auto;">&#160;</td>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Zip Code)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Registrant&#8217;s telephone number, including area code: <b>(<ix:nonNumeric contextRef="d20268K" name="dei:CityAreaCode" id="ixv-428">408</ix:nonNumeric>) <ix:nonNumeric contextRef="d20268K" name="dei:LocalPhoneNumber" id="ixv-429">501-8881</ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not Applicable</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:3.3%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20268K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-430">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:3.3%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20268K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-431">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:3.3%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20268K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-432">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:3.3%;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20268K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-433">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;width:auto;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:16.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></div>
			</td>
			<td style="vertical-align:bottom;width:0.8%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading Symbol(s)</b></div>
			</td>
			<td style="vertical-align:bottom;width:0.9%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:14.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which</b><br/>
			<b>registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:16.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20268K" name="dei:Security12bTitle" id="ixv-434">Common Stock</ix:nonNumeric>, par value $0.0001 per share</div>
			</td>
			<td style="vertical-align:top;width:0.8%;">&#160;</td>
			<td style="vertical-align:top;width:13.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20268K" name="dei:TradingSymbol" id="ixv-435">RVPH</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:14.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20268K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-436">Nasdaq</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="d20268K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-437">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:9.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item</b>&#160;<b>7.01.</b></div>
			</td>
			<td style="vertical-align:top;width:90.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Regulation FD Disclosure.</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On April 15, 2026, Reviva Pharmaceuticals Holdings, Inc. (&#8220;Reviva&#8221; or the &#8220;Company&#8221;) issued a letter to shareholders announcing certain business updates, including in connection with the Company&#8217;s program for the development of brilaroxazine for the treatment of schizophrenia and regarding the Company&#8217;s intellectual property strategy. A copy of the letter to shareholders is attached hereto as Exhibit 99.1.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:9.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item</b>&#160;<b>8.01.</b></div>
			</td>
			<td style="vertical-align:top;width:90.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Other Events.</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Brilaroxazine Program and Intellectual Property Updates</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As described in Item 7.01 of this Current Report on Form 8-K, on April 15, 2026, the Company issued a letter to shareholders announcing certain business updates, including in connection with the Company&#8217;s program for the development of brilaroxazine for the treatment of schizophrenia and regarding the Company&#8217;s intellectual property strategy.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company announced certain efforts centered on extending the long-term value of the brilaroxzine program and preparing for the next phase of development. A component of that strategy is the Company&#8217;s effort to extend patent life and commercial exclusivity for brilaroxazine, potentially through 2046. To support this objective, the Company has filed a composition of matter patent application on a new form of brilaroxazine and will be pursuing an accelerated review process for that application.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on the preclinical development package for this new form of brilaroxazine, the Company is preparing to seek U.S. Food &amp; Drug Administration (&#8220;FDA&#8221;) alignment on using this new form of brilaroxazine product in the Company&#8217;s future new drug application (&#8220;NDA&#8221;) submission. This would include switching the active pharmaceutical ingredient (API) of brilaroxazine and its formulation in the second Phase 3 trial in schizophrenia. The Company believes this type of change is not uncommon in the pharmaceutical industry during late-stage development and prior to NDA filing, particularly when it may strengthen lifecycle management and long-term intellectual property. The Company is optimistic about receiving FDA alignment on this strategy, with feedback expected mid-year 2026.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If successful, this initiative has the potential to meaningfully extend the commercial exclusivity of brilaroxazine and strengthen the Company&#8217;s ability to realize the full value of the program over time. Importantly, a longer exclusivity runway could enhance the opportunity to develop brilaroxazine not only in schizophrenia, but also in bipolar disorder, major depressive disorder, and other potential high-value indications. The Company believes this strategy could materially increase the long-term value of the asset and further improve its attractiveness in future investment and strategic partnering discussions.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At the same time, the Company is moving forward with preparations for the second Phase 3 trial of brilaroxazine in schizophrenia, RECOVER-2. The Company expects to initiate trial related activities in Q2 2026 and begin patient enrollment in the United States in Q3 2026. As previously reported, the FDA has already cleared the protocol for this trial, and the Company currently expects study completion in Q4 2027.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Risk Factors Update</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company hereby updates and supplements its Risk Factor disclosure, as set forth in Part I, Item 1A of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 30, 2026, by adding the below updated supplemental Risk Factor as follows:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The Company is heavily dependent on the success of brilaroxazine, its only advanced product candidate, which is still under clinical development, and if brilaroxazine does not receive regulatory approval or is not successfully commercialized, the Company</i></b>&#8217;<b><i>s business will be harmed.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company currently has no products that are approved for commercial sale and may never be able to develop marketable drug products. The Company expects that a substantial portion of its efforts and expenditures in the foreseeable future will be devoted to brilaroxazine. The Company&#8217;s only other product candidate is RP1208, which is in the pre-clinical phase. The Company does not expect to allocate a significant portion of its efforts or resources to the clinical trials or development of this product candidate in the foreseeable future. Accordingly, the Company&#8217;s business currently depends heavily on the successful development, regulatory approval and commercialization of brilaroxazine. The Company cannot be certain that brilaroxazine will receive regulatory approval or be successfully commercialized even if the Company receives regulatory approval. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of drug products are and will remain subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries that each have differing regulations. The Company is not permitted to market brilaroxazine in the United States until it receives approval of a new drug application, or NDA, from the FDA, or in any foreign countries until it receives the requisite approval from such countries. The Company has not submitted an NDA to the FDA or comparable applications to other regulatory authorities and does not expect to be in a position to do so for the foreseeable future. Obtaining approval of an NDA is an extensive, lengthy, expensive and inherently uncertain process, and the FDA may delay, limit or deny approval of brilaroxazine and the Company&#8217;s other product candidates for many reasons, including:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the Company may not be able to demonstrate that brilaroxazine is safe and effective as a treatment for the Company&#8217;s targeted indications to the FDA&#8217;s satisfaction;</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the FDA may require additional Phase 3 trials of brilaroxazine in schizophrenia, including in connection with the Company&#8217;s plan to switch to a new form of brilaroxazine in the Phase 3 RECOVER-2 trial, which would increase the Company&#8217;s costs and prolong brilaroxazine&#8217;s development;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the results of the Company&#8217;s clinical trials may not meet the level of statistical or clinical significance required by the FDA for marketing approval;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the FDA may disagree with the number, design, size, conduct or implementation of the Company&#8217;s clinical trials;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the contract research organizations, or CROs, that the Company retains to conduct clinical trials may take actions outside of the Company&#8217;s control that materially adversely impact the Company&#8217;s clinical trials;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the FDA may not find the data from preclinical studies and clinical trials sufficient to demonstrate that the clinical and other benefits of brilaroxazine outweigh its safety risks;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the FDA may disagree with the Company&#8217;s interpretation of data from its preclinical studies and clinical trials or may require that the Company conduct additional studies;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the FDA may not accept data generated at the Company&#8217;s clinical trial sites;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">if the Company&#8217;s NDA is reviewed by an advisory committee, the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of the Company&#8217;s application or may recommend that the FDA require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the FDA may require development of a risk evaluation and mitigation strategy, or REMS, as a condition of approval;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the FDA may identify deficiencies in the manufacturing processes or facilities of the Company&#8217;s third-party manufacturers; or</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the FDA may change its approval policies or adopt new regulations.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Forward-Looking Statements</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This Current Report on Form 8-K, including Exhibit 99.1 hereto, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to statements regarding the Company&#8217;s expectations for future periods, anticipated business and financial performance, projections, trends; statements regarding the Company's positioning, its strategies, future progress, plans, goals, focuses and initiatives, and the expected timing and potential benefits thereof; and including statements regarding Company&#8217;s efforts to strengthen its capital position, balance sheet and cash position, preserve strategic flexibility, focus on long-term value, and support the Company&#8217;s development priorities; statements about the Company&#8217;s estimated cash position and projected cash runway; statements about brilaroxazine, including realizing the full potential thereof in schizophrenia and potentially other indications, and advancing the product through key regulatory and clinical milestones; statements about evaluating strategic alternatives as the Company seeks to maximize the value of brilaroxazine and preserve optionality for stockholders; statements about opportunity ahead and the clinical profile of brilaroxazine and its potential; statements about the Company&#8217;s plans and intentions for extending the long-term value of the brilaroxazine program and preparing for the next phase of development, including with respect to extending patent life and commercial exclusivity; statements about plans and intentions for switching to a new form of brilaroxazine product, seeking FDA alignment, future NDA submission, and expected timing, results and benefits of the Company&#8217;s strategy; and statements about the planned RECOVER-2 Phase 3 trial of brilaroxazine in schizophrenia, and the anticipated timing thereof; statements regarding the Company&#8217;s expectations about the anticipated clinical profile of its product candidates, including anticipated efficacy or safety profile; the Company&#8217;s expectations, intentions or beliefs regarding matters including product development and clinical trial plans, clinical and regulatory timelines and expenses, planned or potential additional trials and the timing thereof, planned or intended regulatory submissions and the timing thereof, the timing of availability of additional data or initiation of additional trials, trial results, market opportunity, costs of additional trials including statements about estimated costs, and the risk that the actual cost of trials and the Company&#8217;s actual expenses may be higher than the Company projects in its estimates; statements about ability to raise sufficient funding, including in an amount sufficient to support the Company&#8217;s intended additional trials, statements about expected approvals or the timing at which approval might be anticipated; statements about competitive position, possible or assumed future results of operations, business strategies, potential opportunities for development including partnerships, growth or expansion opportunities and other statements that are predictive in nature; and other statements about the Company&#8217;s goals, plans, strategies, initiatives, and projections about future performance and expected results. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates and management&#8217;s current beliefs and assumptions.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">These statements may be identified by the use of forward-looking expressions, including, but not limited to, &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;potential, &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions and the negatives of those terms. These statements relate to future events or the Company&#8217;s financial performance and involve known and unknown risks, uncertainties, and other factors, on the Company&#8217;s operations, clinical development and clinical trial plans, timelines and estimates, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and the Company&#8217;s other filings from time to time with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:9.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item</b>&#160;<b>9.01.</b></div>
			</td>
			<td style="vertical-align:top;width:90.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Financial Statements and Exhibits.</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>(d) Exhibits.</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following Exhibit 99.1 is furnished with this report:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:4.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Exhibit No.</div>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:41.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Description</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">99.1</div>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:middle;width:41.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_945819.htm" style="-sec-extract:exhibit;">Letter to Shareholders issued by Reviva Pharmaceuticals Holdings, Inc., dated April 15, 2026.</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">104</div>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:middle;width:41.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:15.7%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:5.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>REVIVA PHARMACEUTICALS HOLDINGS, INC.</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:15.7%;">&#160;</td>
			<td style="vertical-align:top;width:5.6%;">&#160;</td>
			<td style="vertical-align:top;width:25%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:15.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: April 15, 2026</div>
			</td>
			<td style="vertical-align:top;width:5.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Narayan Prabhu</i></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:15.7%;">&#160;</td>
			<td style="vertical-align:top;width:5.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name:</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title:</div>
			</td>
			<td style="vertical-align:top;width:25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Narayan Prabhu</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_945819.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_945819.htm</title>

	<!-- Generated by ThunderDome Portal - 4/15/2026 12:06:02 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Reviva Announces Letter to Shareholders</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">CUPERTINO, Calif., April 15, 2026 &#8212; Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (&#8220;Reviva,&#8221; the &#8220;Company&#8221; &#8220;we&#8221; or &#8220;us&#8221;), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced a letter to shareholders from Founder, President, and CEO, Laxminarayan Bhat, Ph.D.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The full text of the letter follows.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Dear Fellow Shareholders:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The past year has been an important and challenging period for Reviva Pharmaceuticals. We have made difficult but necessary decisions to strengthen our capital position, preserve strategic flexibility, and keep the Company focused on what we believe is the most important driver of long-term value: realizing the full potential of brilaroxazine across schizophrenia and potentially other neuropsychiatric indications.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We recognize that the recent reverse stock split and financing have been difficult for stockholders, particularly in light of the pressure on our share price. These actions were not taken lightly. Always mindful first and foremost to advancing the best interests of our stockholders, these actions were undertaken to strengthen our balance sheet, support our development priorities, and position Reviva to advance brilaroxazine through the next key regulatory and clinical milestones. On March 20, 2026, we closed the aforementioned $10 million financing to further strengthen our cash position. Immediately following this capital raise, we had approximately $23 million in cash and cash equivalents (unaudited), which we believe will fund operations into Q1 2027. In parallel, we are also evaluating strategic alternatives as we seek to maximize the value of brilaroxazine and preserve optionality for stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our conviction in the opportunity ahead continues to be grounded in the clinical profile of brilaroxazine. Based on the data generated to date, we believe brilaroxazine has demonstrated the potential to be a differentiated treatment option in schizophrenia, with encouraging durable efficacy, safety and tolerability. These results continue to support our belief that the program has the potential to address meaningful unmet needs and serve as the foundation for a broader long-term franchise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Looking ahead, our focus is on achieving a clear set of milestones for brilaroxazine from Q2 through Q4 2026, centered on extending the long-term value of the program and preparing for the next phase of development. A central component of that strategy is our effort to extend patent life and commercial exclusivity for brilaroxazine, potentially through 2046. To support this objective, we have filed a composition of matter patent application on a new form of brilaroxazine and will be pursuing an accelerated review process for that application.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on the preclinical development package for this new form of brilaroxazine, we are preparing to seek U.S. Food &amp; Drug Administration (&#8220;FDA&#8221;) alignment on using this new form of brilaroxazine product in our future new drug application (&#8220;NDA&#8221;) submission. This would include switching the active pharmaceutical ingredient (API) of brilaroxazine and its formulation in the second Phase 3 trial in schizophrenia. We believe this type of change is not uncommon in the pharmaceutical industry during late-stage development and prior to NDA filing, particularly when it may strengthen lifecycle management and long-term intellectual property. We are optimistic about receiving FDA alignment on this strategy, with feedback expected mid-year 2026.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If successful, this initiative has the potential to meaningfully extend the commercial exclusivity of brilaroxazine and strengthen our ability to realize the full value of the program over time. Importantly, a longer exclusivity runway could enhance the opportunity to develop brilaroxazine not only in schizophrenia, but also in bipolar disorder, major depressive disorder, and other potential high-value indications. We believe this strategy could materially increase the long-term value of the asset and further improve its attractiveness in future investment and strategic partnering discussions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At the same time, we are moving forward with preparations for the second Phase 3 trial of brilaroxazine in schizophrenia, RECOVER-2. We expect to initiate trial related activities in Q2 2026 and begin patient enrollment in the United States in Q3 2026. As previously reported, the FDA has already cleared the protocol for this trial, and we currently expect study completion in Q4 2027. We believe the recent capital raise will help support these efforts and enable us to advance the program through some of these important milestones.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">While recent months have been challenging, we believe the path forward is defined by a focused and achievable set of priorities: securing FDA alignment on strategy to switch to the new form of brilaroxazine product in the ongoing clinical development, advancing our patent and exclusivity initiatives, initiating RECOVER-2, and positioning brilaroxazine to capture its broader potential across neuropsychiatric indications. We remain focused on disciplined execution and on taking the steps we believe are necessary to unlock the full value of this program.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Sincerely,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Laxminarayan Bhat, Ph.D.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Founder, President, and CEO</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Brilaroxazine</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Brilaroxazine is an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in the pathophysiology of several conditions including schizophrenia, psoriasis and interstitial lung diseases like pulmonary hypertension, pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Positive topline data from the global Phase 3 RECOVER trial in schizophrenia demonstrated the trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains including reduction in key proinflammatory cytokines implicated in the pathophysiology of schizophrenia and comorbid inflammatory conditions at week 4 with 50 mg of brilaroxazine vs. placebo, with a generally well-tolerated side effect profile comparable to placebo and discontinuation rates&nbsp;<i>lower</i>&nbsp;than placebo. Positive data from a clinical drug-drug interaction (DDI) study investigating the potential effect of the CYP3A4 enzyme on brilaroxazine in healthy subjects supports no clinically significant interaction when combined with CYP3A4 inhibitors. Reviva believes that a full battery of regulatory compliant toxicology and safety pharmacology studies has been completed for brilaroxazine. Reviva intends to develop brilaroxazine for other neuropsychiatric indications including bipolar disorder, major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Additionally, brilaroxazine has shown promising nonclinical activity for inflammatory diseases psoriasis, pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) with mitigation of fibrosis and inflammation in translational animal models. Brilaroxazine has already received Orphan Drug Designation by the FDA for the treatment of PAH and IPF conditions. To learn more about the clinical and preclinical data available for brilaroxazine, please visit&nbsp;<u>revivapharma.com/publications</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About Reviva</b>&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva&#8217;s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva&#8217;s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Cautionary Language Concerning Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This letter to shareholders contains &#8220;forward-looking statements&#8221; within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the Company&#8217;s expectations for future periods, anticipated business and financial performance, projections, trends; statements regarding the Company's positioning, its strategies, future progress, plans, goals, focuses and initiatives, and the expected timing and potential benefits thereof; and including statements regarding Company&#8217;s efforts to strengthen its capital position, balance sheet and cash position, preserve strategic flexibility, focus on long-term value, and support the Company&#8217;s development priorities; statements about the Company&#8217;s estimated cash position and projected cash runway; statements about brilaroxazine, including realizing the full potential thereof in schizophrenia and potentially other indications, and advancing the product through key regulatory and clinical milestones; statements about evaluating strategic alternatives as the Company seeks to maximize the value of brilaroxazine and preserve optionality for stockholders; statements about opportunity ahead and the clinical profile of brilaroxazine and its potential; statements about the Company&#8217;s plans and intentions for extending the long-term value of the brilaroxazine program and preparing for the next phase of development, including with respect to extending patent life and commercial exclusivity; statements about plans and intentions for switching to the new form of brilaroxazine product, seeking FDA alignment, future NDA submission, and expected timing, results and benefits of the Company&#8217;s strategy; and statements about the planned RECOVER-2 Phase 3 trial of brilaroxazine in schizophrenia, and the anticipated timing thereof; statements regarding the Company&#8217;s expectations about the anticipated clinical profile of its product candidates, including anticipated efficacy or safety profile; the Company&#8217;s expectations, intentions or beliefs regarding matters including product development and clinical trial plans, clinical and regulatory timelines and expenses, planned or potential additional trials and the timing thereof, planned or intended regulatory submissions and the timing thereof, the timing of availability of additional data or initiation of additional trials, trial results, market opportunity, costs of additional trials including statements about estimated costs, and the risk that the actual cost of trials and the Company&#8217;s actual expenses may be higher than the Company projects in its estimates; statements about ability to raise sufficient funding, including in an amount sufficient to support the Company&#8217;s intended additional trials, statements about expected approvals or the timing at which approval might be anticipated; statements about competitive position, possible or assumed future results of operations, business strategies, potential opportunities for development including partnerships, growth or expansion opportunities and other statements that are predictive in nature; and other statements about the Company&#8217;s goals, plans, strategies, initiatives, and projections about future performance and expected results. These forward-looking statements are made as of the date of this letter to shareholders and are based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;should,&#8221; &#8220;believe,&#8221; &#8220;hope,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;outlook,&#8221; &#8220;goals,&#8221; &#8220;estimate,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company&#8217;s control. The Company&#8217;s actual results could differ materially from those stated or implied in the Company&#8217;s forward-looking statements (including without limitation any of its projections) due to a number of factors, including but not limited to the risks detailed in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in subsequent reports filed by the Company with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In light of the risks and uncertainties impacting the Company&#8217;s business, there can be no assurance that any forward-looking statement will in fact prove to be correct. Past performance is not necessarily indicative of future results. The forward-looking statements included in this letter to shareholders represent the Company&#8217;s views as of the date of this letter to shareholders. The Company anticipates that subsequent events and developments will cause its views to change. The Company undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company&#8217;s views as of any date subsequent to the date of this letter to shareholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Corporate Contact:</b><br>
Reviva Pharmaceuticals Holdings, Inc.<br>
Laxminarayan Bhat, PhD&nbsp;<br>
<u>www.revivapharma.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rvph-20260415.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 4/14/2026 11:12:14 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:rvph="http://www.rvph.com/20260415" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.rvph.com/20260415">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/cyd-8k-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-8k-sub-2024.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvph-20260415_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvph-20260415_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvph-20260415_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.rvph.com/20260415/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="rvph_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>rvph-20260415_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 4/14/2026 11:12:14 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.rvph.com/20260415/role/statement-document-and-entity-information" xlink:href="rvph-20260415.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.rvph.com/20260415/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>rvph-20260415_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 4/14/2026 11:12:14 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line Two</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>rvph-20260415_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 4/14/2026 11:12:14 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.rvph.com/20260415/role/statement-document-and-entity-information" xlink:href="rvph-20260415.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.rvph.com/20260415/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 15, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">REVIVA PHARMACEUTICALS HOLDINGS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Apr. 15,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-38634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">85-4306526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">10080 N Wolfe Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity, Address, Address Line Two</a></td>
<td class="text">Suite SW3-200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Cupertino<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">501-8881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RVPH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001742927<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rvph20260414_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rvph.com/20260415/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>rvph-20260415.xsd</File>
    <File>rvph-20260415_def.xml</File>
    <File>rvph-20260415_lab.xml</File>
    <File>rvph-20260415_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="rvph20260414_8k.htm">rvph20260414_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rvph20260414_8k.htm": {
   "nsprefix": "rvph",
   "nsuri": "http://www.rvph.com/20260415",
   "dts": {
    "schema": {
     "local": [
      "rvph-20260415.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-8k-sub-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-cr-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "rvph-20260415_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "rvph-20260415_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rvph-20260415_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "rvph20260414_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 36,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.rvph.com/20260415/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20268K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rvph20260414_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20268K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rvph20260414_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAxis",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Axis]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentDomain",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Domain]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r8"
     ]
    },
    "cyd_MaterialCybersecurityIncidentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Table]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.rvph.com/20260415/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001437749-26-012303-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-26-012303-xbrl.zip
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M!U8BEE<)MEGX$ZYGFF<.0 $E5_=1@-]8>TVGQF(Z8GZS/T.N"W@BL7&@-WT
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M-A0>X:7EFMI5_+KUW+NZ?';PQ9-@TJXN#X\.OH*EL>08Q\KE,%8DKZH73*8
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M9J?%EIF,*#"1/&3)/<[#"DJE.$O<=J']3.<LET R^96D9=2J8%:9#7!QA:6
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M"3;\\^.Q1/VHO_7BG7\!4$L#!!0    ( *5 CUP;ZK*G02   $/$   3
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M1"V,Y)<(DR@(Z+:-X/@,$\($U&Q"O[RFN2;KDAYP(74QI6U.J8&"?!F9"P\
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M6U!AQ6$QRUZD4O>O*/2B"- /$P.I6E!EV+G.<$PGXP;[,E@*S5565YTL:*-
M(VE2T%W"=,A65X^KL8Q1[=1MG$FRQ=AT&9&W-%,1M71.EE=OQ=A_0R<*PRV!
MJ@ 'V*U^9[&T-;JOX13N\>948$<G-Q,66K[5W,LBQD"3"B24N,YTPO,,;/\6
M4W0TPR5SI*Y3+0/HAT76V\R^\*!YLP]=QX;D3O2A$<FE'GW1!MQ%UXXBEF.V
M8QDS:8*(-G')R? \K6>\-^>>#",R+CM9)(ME6HF:O6+3BE&6*S%T4PD,JE$,
M@(J"ZK95I;[UNNV+:7XMZ'SVB68UL[\B0L_^9AI+S/YL$6MN"DO?^=8,Q<T-
MU @X^[,:8^[F[*^4T&E_(RT*0( ]-1Q0Y7(A%"-C 9!"AO8YJKPY196TH(!2
M'R)+E8*:"+(%-0.5=K?122^B 'C*>1A=FIA+J/]-R1#UHLHGE98U:(8SU)7Z
M=5L;.%>TXW#4RN9,BU68&56E8 6:G,E#R!$'C>3,!;U[.F3WH&G"@H:34MV4
MDW.DR]E($F(J )6*E>3"]?.9&S2JSR0.'/I8S/N:[)0:D)HV![8'D[[M4A5_
M%4PGD=)%:[#I>RO?O[;H2G=#4J:X3DX(Y^B_=ZCV;V*_1K*IM/C"=BMX>I0#
M<)&(),4W"@ ' -J@FV3DGI(:^+9QZT+ 6N2 9?BY*7+/+1LJD;VY56*YMH\*
MWS&YC>JIG<^FXR8S^-,+;+\&6V=8O;=Z_C44BF)I[,+MH,GG-"BNSQ-SWK#W
M<>3.LD1G6:+S793HW$'S^?$:(&\_V0;(;W.]Y-2Q#DB(4'1FV159MT9:\5^X
M('GV39%T2Y^Y,)U43G]^HW]0IA8*\J=3\/UXS.R.G^*<2-\/A-G$^D-_U;42
M&^S]'T45X?U;?N%PXUZ_3UH&2ONAOR19"94#:@9.'HG[^=CHXUPN$O5#W>IW
M>&NO.!LG^+T\<?7?[?6-K?9V<YQ.<K: 7\QKP!18K;,C--[#6Q_SKNRGY0_%
M4-=V,#AO]>6>.M.-U,J-X(&F^#U]KO9Q,*C=6O^!$&B?>L2>8 MC_!J"Z6;*
M#C L\A9#62MHW/N^D8[&B= +T9?"_GS3_\C\R,M0R_I^OQZ__ S?$_\,WX.0
MPX*O=)_VWAUUSS[W#T^?=6*;VY-B[27MY,3YL&;>O"HQ%M1M/Q^E7RQ],-3/
M N-<]5WEVGA/L7Y81VTP\#@08QX,\Y@ NLO, (SL9OCU)YK.=+3ZA[HR+G7T
M+W4XM#>:FPM$%C /.$/XNM:IW3C-QC?XK/Q@KW_X>^_W+CMYW^U_ZNX??C[K
M[7<_GK+WQQ\/>D?O3D$I.=J_WKB_D_9Q#6QN"8\O>+-3H4%\S>8?\DH.4/O;
MF5'_OE!U^@88]&:Z<_WF[FBTS5[:@V*_W%M5J^R()WS*0W:2\,$X<YPVCX[J
MWUAK/>(3D3MG'A#N9S(-Q UH\XAH,8L/#PZ/_;$40U:X6(\QG4<LKH1Y;,W_
MWK&QXN/VMUOV6QWO(0VHC]W3LT9AL51&X>XUNF8W ?\P6#1.)\'>_P-02P$"
M% ,4    " "E0(]<C_\)5AD6  "73@  #0              @ $     97A?
M.30U.#$Y+FAT;5!+ 0(4 Q0    ( *5 CUQ^)SRD@0,  !H.   1
M      "  406  !R=G!H+3(P,C8P-#$U+GAS9%!+ 0(4 Q0    ( *5 CUSP
MVU1%T00  .,L   5              "  ?09  !R=G!H+3(P,C8P-#$U7V1E
M9BYX;6Q02P$"% ,4    " "E0(]<[S(I4NT%  ! /   %0
M@ 'X'@  <G9P:"TR,#(V,#0Q-5]L86(N>&UL4$L! A0#%     @ I4"/7/29
MR>AM!   >RT  !4              ( !&"4  ')V<&@M,C R-C T,35?<')E
M+GAM;%!+ 0(4 Q0    ( *5 CUP;ZK*G02   $/$   3              "
M ;@I  !R=G!H,C R-C T,31?.&LN:'1M4$L%!@     &  8 A $  "I*
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>rvph20260414_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rvph-20260415.xsd" xlink:type="simple"/>
    <context id="d20268K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
        </entity>
        <period>
            <startDate>2026-04-15</startDate>
            <endDate>2026-04-15</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20268K" id="ixv-407">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20268K" id="ixv-408">0001742927</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20268K" id="ixv-418">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20268K" id="ixv-419">2026-04-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20268K" id="ixv-420">REVIVA PHARMACEUTICALS HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20268K" id="ixv-421">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20268K" id="ixv-422">001-38634</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20268K" id="ixv-423">85-4306526</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20268K" id="ixv-424">10080 N Wolfe Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="d20268K" id="ixv-425">Suite SW3-200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="d20268K" id="ixv-426">Cupertino</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20268K" id="ixv-427">CA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode contextRef="d20268K" id="ixv-428">408</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20268K" id="ixv-429">501-8881</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20268K" id="ixv-430">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20268K" id="ixv-431">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20268K" id="ixv-432">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20268K" id="ixv-433">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20268K" id="ixv-434">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20268K" id="ixv-435">RVPH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20268K" id="ixv-436">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20268K" id="ixv-437">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
